[go: up one dir, main page]

MX2018005411A - Polipeptidos anti il-23. - Google Patents

Polipeptidos anti il-23.

Info

Publication number
MX2018005411A
MX2018005411A MX2018005411A MX2018005411A MX2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequences
linkers
seq
relates
Prior art date
Application number
MX2018005411A
Other languages
English (en)
Inventor
Buyse Marie-Ange
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2018005411A publication Critical patent/MX2018005411A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a secuencias de aminoácidos que están dirigidas en contra de IL-23. Las secuencias de aminoácidos de la presente invención comprenden dos nanoanticuerpos anti IL-23 y un nanocuerpo anti albúmina de suero, unidos por dos conectores (conectores 9GS). En particular, la invención se refiere a las secuencias de aminoácidos de SEQ ID NO: 2 y SEQ ID NO: 3 (enumeradas en la Tabla 1 y la Figura 1).
MX2018005411A 2015-10-30 2016-10-28 Polipeptidos anti il-23. MX2018005411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248468P 2015-10-30 2015-10-30
PCT/EP2016/076076 WO2017072299A1 (en) 2015-10-30 2016-10-28 Polypeptides against il-23

Publications (1)

Publication Number Publication Date
MX2018005411A true MX2018005411A (es) 2018-08-15

Family

ID=57218890

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005411A MX2018005411A (es) 2015-10-30 2016-10-28 Polipeptidos anti il-23.

Country Status (13)

Country Link
US (2) US10968271B2 (es)
EP (1) EP3368569B1 (es)
JP (1) JP6936797B2 (es)
KR (1) KR20180072819A (es)
CN (1) CN108350069B (es)
AU (1) AU2016347610A1 (es)
BR (1) BR112018008754A2 (es)
CA (1) CA3003539A1 (es)
IL (1) IL258897A (es)
MX (1) MX2018005411A (es)
RU (1) RU2018119732A (es)
SG (1) SG11201803416VA (es)
WO (1) WO2017072299A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) * 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CN114920839B (zh) * 2022-06-17 2023-03-10 天津大学 特异性结合il-23的纳米抗体及其用途
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
WO2010142534A1 (en) * 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
CN102971341A (zh) * 2010-04-30 2013-03-13 埃博灵克斯股份有限公司 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列
AU2011282476B2 (en) * 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
DE102011077786A1 (de) 2011-06-20 2012-12-20 Continental Teves Ag & Co. Ohg Aktuatorsystem und Betriebsverfahren für ein Aktuatorsystem
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102143506B1 (ko) 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン.ヴェー. 改良された血清アルブミン結合剤

Also Published As

Publication number Publication date
BR112018008754A2 (pt) 2018-10-30
US20180312583A1 (en) 2018-11-01
CN108350069A (zh) 2018-07-31
EP3368569A1 (en) 2018-09-05
AU2016347610A1 (en) 2018-05-10
RU2018119732A (ru) 2019-12-03
US11753465B2 (en) 2023-09-12
SG11201803416VA (en) 2018-05-30
US10968271B2 (en) 2021-04-06
CN108350069B (zh) 2021-11-12
IL258897A (en) 2018-06-28
KR20180072819A (ko) 2018-06-29
US20210188967A1 (en) 2021-06-24
JP6936797B2 (ja) 2021-09-22
JP2018538251A (ja) 2018-12-27
RU2018119732A3 (es) 2020-03-24
WO2017072299A1 (en) 2017-05-04
CA3003539A1 (en) 2017-05-04
EP3368569B1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
MX2018005411A (es) Polipeptidos anti il-23.
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12018501355A1 (en) Rsv f protein mutants
PH12019500596B1 (en) Recombinant binding proteins and their use
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX382929B (es) Polipéptido heterodimerizado.
SG10201909716RA (en) Modified j-chain
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014CN00414A (es)
NZ628625A (en) Polypeptides binding to human complement c5
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
EA201690651A1 (ru) Содержащие cmp высокобелковые композиции денатурированного сывороточного белка, содержащие их продукты и их применения
MX384984B (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
WO2014136064A3 (en) Immunogenic fusion polypeptides
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EP4374913A3 (en) Novel human serum albumin mutant
MY176200A (en) Binding polypeptides having a mutated scaffold
IN2015DN03206A (es)
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins